Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Brain Blood Flow and Cerebral Autoregulation Monitoring in Critically Ill Children

24 de agosto de 2026 actualizado por: University of Wisconsin, Madison

Transcranial Doppler Assessment of Cerebral Autoregulation and Blood Flow Velocity Patterns in Critically Ill Children: A Prospective Observational Study

This study uses a non-invasive (external) ultrasound test called Transcranial Doppler (TCD) to measure how blood flows through the major arteries of the brain of children receiving care in the Pediatric Intensive Care Unit (PICU). TCD is already used for clinical reasons in many children, but it is not part of routine monitoring for every critically ill child. By using TCD, the investigators hope to better understand how brain blood flow changes during illness. They will also track children's functional status from before their illness to the time of PICU discharge to explore how brain blood flow patterns relate to neurological outcomes.125 participants will be enrolled and will be on study while in the PICU, estimated to be 3-14 days.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Current clinical management of hemodynamics in critically ill children relies primarily on systemic parameters (e.g., blood pressure, heart rate) rather than direct assessment of cerebrovascular regulation. This approach may overlook individual variations in cerebral autoregulation (CA) capacity, potentially leading to suboptimal cerebral perfusion.

By prospectively evaluating TCD-derived CA indices in intubated pediatric patients with arterial blood pressure monitoring, this study aims to:

  1. Establish normative Cerebral blood flow velocity (CBFV) ranges for critically ill children
  2. Describe CBFV patterns across critically ill pediatric populations with varying neurologic risk profiles
  3. Characterize the prevalence of CA dysfunction in a heterogeneous PICU population
  4. Explore associations between CA/CBFV and functional outcomes

These data could:

  1. Provide age-stratified CBFV reference values for the PICU setting
  2. Identify patients at highest risk of neurological morbidity using population-specific thresholds
  3. Inform future trials of autoregulation-guided hemodynamic management

Tipo de estudio

De observación

Inscripción (Estimado)

125

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Meg Baker
  • Número de teléfono: meg.baker@wisc.edu
  • Correo electrónico: meg.baker@wisc.edu

Ubicaciones de estudio

  • Estados Unidos
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792
        • Reclutamiento
        • American Family Children's Hospital PICU
        • Sub-Investigador:
          • Talal Al Hendawi, MD
        • Investigador principal:
          • Neil Munjal, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Mechanically ventilated pediatric patients (1 day-17.5 years) admitted to the PICU who meet eligibility criteria

Descripción

Inclusion Criteria:

  • Has at least one Parent or Legal Guardian who is willing and able to provide informed consent in English
  • Mechanically ventilated (Endotracheal tube)
  • Indwelling arterial catheter
  • Current patient in the American Family Children's Hospital PICU.
  • 1 day to 17.5 years of age

Exclusion Criteria:

  • Subjects with a known or obvious anatomic barrier preventing safe application of the transcranial Doppler probe (e.g., cranial dressings, cranial fixation hardware, ventricular access devices positioned over insonation sites, or bilateral craniectomies)
  • Patient with known chronic hypertension
  • Admission FSS score > 16
  • Tracheostomized patient
  • The designated sub-investigator (Dr. Talal Al Hendawi) and PI (Dr. Neil Munjal) are unavailable to perform the Transcranial Doppler scan at the time of eligibility. All study scans are performed by either Dr. Al Hendawi or Dr.Munjal to ensure standardization and data integrity. Therefore, if they are unavailable (e.g., due to clinical service, leave, or other scheduling constraints), the patient will not be enrolled in the study.
  • Not suitable for study participation due to other reasons at the discretion of the investigators

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
PICU Patients
Mechanically ventilated pediatric patients (1 day-17.5 years) admitted to the PICU.
Dispositivo: Transcranial Doppler
TCD measurements synchronized to arterial blood pressure and ventilatory data, performed once daily for up to 5 days during PICU admission plus one additional pre-extubation scan if applicable, approximately 30 minutes each. Bilateral middle cerebral artery (MCA) insonation performed at each session.
Otros nombres:
  • TCD

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Functional Status Scale (FSS) from baseline to PICU discharge
Periodo de tiempo: Baseline FSS reflects pre-morbid functional status as reported by parents/guardians at enrollment; follow-up FSS assessed at PICU discharge (estimated 3-14 days)
To assess the relationship between cerebral autoregulation and neurological outcomes in critically ill pediatric patients, FSS will be measured. FSS has 6 domains: mental status, sensory, communication, motor function, feeding, and respiratory. FSS is scored from 6 to 30, higher scores are indicative of more severe dysfunction.
Baseline FSS reflects pre-morbid functional status as reported by parents/guardians at enrollment; follow-up FSS assessed at PICU discharge (estimated 3-14 days)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean Flow Index (Mx)
Periodo de tiempo: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Mean Flow Index (Mx) will serve as the primary exposure variable in multivariable regression analyses relating cerebral autoregulation status to functional outcome, and will additionally be characterized across PICU subpopulations.
data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Percent successful exams (complete bilateral MCA data)
Periodo de tiempo: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Feasibility metric reflecting the proportion of TCD sessions yielding complete bilateral MCA data, used to assess protocol feasibility and sonographic success rates in the PICU setting.
data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Time per exam (min)
Periodo de tiempo: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Feasibility metric reflecting total time required per TCD session, used to assess protocol efficiency and burden on clinical care.
data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Mean CBFV
Periodo de tiempo: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
To describe cerebral blood flow velocity patterns in critically ill pediatric patients, mean CBFV will be measured.
data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Age-stratified CBFV values across pre-specified clinical subgroups (TBI, cardiac arrest, ECMO)
Periodo de tiempo: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
Age-stratified Mx values across pre-specified clinical subgroups (TBI, cardiac arrest, ECMO)
Periodo de tiempo: data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)
data collected while in PICU, from consent (baseline) to discharge (estimated 3-14 days)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

University of Wisconsin, Madison

Investigadores

  • Investigador principal: Neil Munjal, MD, UW School of Medicine and Public Health

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de agosto de 2026

Finalización primaria (Estimado)

1 de mayo de 2028

Finalización del estudio (Estimado)

1 de mayo de 2028

Fechas de registro del estudio

Enviado por primera vez

21 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

21 de mayo de 2026

Publicado por primera vez (Actual)

29 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 2026-0238
  • SMPH/Pediatrics/Critical Care (Otro identificador: UW Madison)
  • Protocol Version 3/3/26 (Otro identificador: UW Madison)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir